清燥救肺汤对特发性肺纤维化肺损伤修复作用及骨桥蛋白、生物标志物和血清FGF-21、HIF-1α的影响  

Effects of Qingzao Jiufei Decoction(清燥救肺汤)on Lung Injury Repair,Biomarkers,and Serum FGF-21 and HIF-1αin Idiopathic Pulmonary Fibrosis

作　　者：赵地 赵添[2] 薛晓彤 梁瑞婷 张欣雨 ZHAO Di;ZHAO Tian;XUE Xiaotong;LIANG Ruiting;ZHANG Xinyu(Department of Traditional Chinese Medicine,Shandong Public Health Clinical Center,Jinan 250132,China;Medical Service Section,The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine,Jinan 250001,China;Department of Traditional Chinese Medicine,Shandong Provincial Taishan Hospital,Tai’an 271099,China;Respiratory Department,Shandong Public Health Clinical Center,Jinan 250132,China)

机构地区：[1]山东省公共卫生临床中心中医科,山东济南250132 [2]山东中医药大学第二附属医院医务部,山东济南250001 [3]山东省泰山医院中医科,山东泰安271099 [4]山东省公共卫生临床中心呼吸科,山东济南250132

出　　处：《山东中医杂志》2024年第11期1223-1229,共7页Shandong Journal of Traditional Chinese Medicine

基　　金：山东省中医药科技计划项目(编号:M-2023277)。

摘　　要：目的:观察清燥救肺汤对特发性肺纤维化患者肺损伤修复作用及生物标志物和血清成纤维细胞生长因子-21(FGF-21)、缺氧诱导因子-1α(HIF-1α)的影响。方法:选择122例特发性肺纤维化患者按随机数字表法分为对照组和观察组各61例。对照组行常规西医治疗,观察组在对照组治疗基础上,同时口服清燥救肺汤。比较两组治疗后临床疗效,治疗前后给予两组中医证候积分评价,给予患者6 min步行距离(6MWT)、圣乔治呼吸问卷(SGRQ)评价,检测患者肺总量(TLC)、一氧化碳弥散量(DLCO)、肺活量(VC)水平,检测患者基质金属蛋白酶-7(MMP-7)、骨桥蛋白、FGF-21、HIF-1α、Ⅱ型肺泡细胞表面抗原(KL-6)、白细胞介素-8(IL-8)水平。结果:治疗后观察组患者总有效率高于对照组(P<0.05);观察组中医证候积分较对照组低(P<0.05);观察组6MWT水平、SGRQ评分较对照组高(P<0.05);观察组TLC、DLCO、VC水平较对照组高(P<0.05);观察组MMP-7、骨桥蛋白、KL-6水平较对照组低(P<0.05);观察组患者FGF-21、HIF-1α水平高于对照组(P<0.05),观察组IL-8水平低于对照组(P<0.05)。结论:清燥救肺汤治疗特发性肺纤维化患者,可提升抗炎作用及肺损伤修复作用,降低生物标志物水平,缓解病情,提升患者运动耐力、生活质量及临床疗效。Objective:To observe the effects of Qingzao Jiufei Decoction(清燥救肺汤)on lung injury repair in patients with idiopathic pulmonary fibrosis(IPF),as well as its impact on biomarkers,and serum levels of fibroblast growth factor-21(FGF-21)and hypoxia-inducible factor-1α(HIF-1α).Methods:A total of 122 IPF patients were randomly divided into a control group and an observation group,61 patients in each group.The control group received conventional western medicine treatment,while the observation group received additional Qingzao Jiufei Decoction treatment.The clinical efficacy,traditional Chinese medicine(TCM)syndrome scores,6-minute walk test(6MWT),St.George’s Respiratory Questionnaire(SGRQ)scores,total lung capacity(TLC),diffusing capacity for carbon monoxide(DLCO),and vital capacity(VC)were compared between the two groups.Levels of matrix metalloproteinase-7(MMP-7),osteopontin,FGF-21,HIF-1α,typeⅡalveolar cell surface antigen(KL-6),and interleukin-8(IL-8)were also measured.Results:After treatment,the total efficacy rate was higher in the observation group than in the control group(P<0.05).The TCM syndrome scores were lower in the observation group(P<0.05),while the 6MWT performance and SGRQ scores were higher in the observation group(P<0.05).The levels of TLC,DLCO,and VC were significantly higher in the observation group(P<0.05).Levels of MMP-7,osteopontin,and KL-6 were lower in the observation group(P<0.05),while FGF-21 and HIF-1αlevels were higher(P<0.05),and IL-8 levels were lower(P<0.05)compared to the control group.Conclusion:Qingzao Jiufei Decoction could enhance anti-inflammatory effects and promote lung injury repair in IPF patients,reduce biomarker levels,alleviate disease progression,and improve exercise capacity,quality of life and clinical efficacy.

关 键 词：清燥救肺汤 特发性肺纤维化 肺损伤修复 生物标志物 骨桥蛋白 成纤维细胞生长因子-21 缺氧诱导因子-1α 

分 类 号：R289.5[医药卫生—方剂学] R256.14[医药卫生—中药学]